Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU regulators dismiss soy heart health claim

This article was originally published in The Tan Sheet

Executive Summary

The European Food Safety Authority concludes that a cause and effect relationship is not established between the consumption of soy protein and lower levels of low-density lipoprotein cholesterol, which lowers the risk of coronary heart disease. Though petitioners submitted 40 studies, the regulatory authority rejected most because they did not test soy protein but soy protein isolate or soy foods containing other substances that have a proven effect on heart health. The petitioners submitted four additional meta-analyses, all of which EFSA said failed to show a relationship between the consumption of soy protein and lower levels of LDL. The soy heart health claim also is under fire in the U.S., where nutrition groups submitted a 2008 citizen petition to FDA to have the health claim overturned and the American Heart Association recommended the claim be revoked (1"The Tan Sheet" Sept. 1, 2008)

You may also be interested in...



Soy Protein Under Fire, But Experts, Industry Confident In Heart Health Claim

Nutrition experts say a citizen petition requesting FDA revoke a health claim linking soy protein to heart health benefits weakens its own argument by citing data selectively and in error

Pipeline Watch: Phase III Readouts For Surufatinib, Tislelizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)

A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.

Topics

UsernamePublicRestriction

Register

PS104401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel